Acupuncture for Functional Dyspepsia: a Functional Magnetic Resonance Imaging (fMRI) Study

Overview

He-Mu-point combination(ST36 and CV12) is one of the most commonly used acupoints combination with synergistic effect for functional dyspepsia(FD). The investigators design the trial to identify the efficacy and explore the central integrated mechanism of puncturing at He-Mu-point combination on FD with functional magnetic resonance imaging (fMRI).

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Double (Participant, Outcomes Assessor)
  • Study Primary Completion Date: December 2017

Detailed Description

105 participants with functional dyspepsia will be allocated into three groups: Low-He point group, Mu point group and He-Mu-point combination group.Every participant will receive 20 sessions of manual acupuncture treatment during 4 weeks. Clinical evaluations will be assessed three times, as measured after randomization, 10 and 20 sessions of treatment.The fMRI scans will be conducted twice, after randomization and treatment completion.

Interventions

  • Other: acupuncture
    • Manual acupuncture treatment will be conducted. thirty minutes duration every time, five times per week for one course, a total four courses.

Arms, Groups and Cohorts

  • Experimental: Low-He point(ST36)
    • Zusanli (ST36, the Low-He point of stomach) is the most important point for gastrointestinal disorder, including functional dyspepsia. Everyone in the group will be punctured at unilateral Zusanli.
  • Experimental: Mu point(CV12)
    • Zhongwan (CV12, the Mu point of stomach) is also good at regulating gastric function. Everyone in the group will be punctured at Zhongwan.
  • Active Comparator: He-Mu-point combination(ST36 and CV12)
    • In traditional Chinese acupuncture theory,synergistic effect can be produced by acupoints combination and the He-Mu-point combination is a classical acupoints combination formula for gastrointestinal diseases. Everyone in the group will be punctured at unilateral Zusanli and Zhongwan.

Clinical Trial Outcome Measures

Primary Measures

  • Nepean Dyspepsia Index (NDI)
    • Time Frame: 4 weeks after allocation

Secondary Measures

  • Self-Rating Anxiety Scale
    • Time Frame: 0 day,2, 4weeks after allocation
  • Self-Rating Depression Scale
    • Time Frame: 0 day,2, 4weeks after allocation
  • Leeds dyspepsia questionnaire
    • Time Frame: 0 day,4 weeks after allocation
  • brain MRI data
    • Time Frame: 0 day,4weeks after allocation
  • The incidence of adverse events during the 4 weeks
    • Time Frame: 4weeks after allocation

Participating in This Clinical Trial

Inclusion Criteria

1. right handed,age between 18 and 45 years old, college degree or above;

2. match the Rome III criteria on FD;

3. no local organic disease by gastroscope examination;

4. before entering the study, without taking any prokinetic agents at least 15days and participating in other clinical study;

5. signing an informed consent in writing by the participant or the immediate family member.

Exclusion Criteria

1. consciousness, cannot express subjective symptoms and psychiatric participants;

2. participants with advanced cancer or other serious wasting diseases, easy to be infected and bleeding;

3. complicating with severe cardiovascular, hepatic,nephritic,digestive, hematopoietic system diseases;

4. impregnate or lactation female;

5. severe depression and anxiety symptoms;

6. female with serious dysmenorrhea;

7. obvious headache, migraine, history of head injury.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 45 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Chengdu University of Traditional Chinese Medicine
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Fang Zeng, professor, Study Chair, Chengdu University of Traditional Chinese Medicine

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.